VanEck Biotech ETF (NASDAQ:BBH) Short Interest Update

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 1,700 shares, an increase of 112.5% from the December 31st total of 800 shares. Based on an average daily volume of 9,000 shares, the short-interest ratio is presently 0.2 days.

VanEck Biotech ETF Stock Performance

BBH traded up $1.29 during midday trading on Thursday, hitting $165.04. 6,285 shares of the company traded hands, compared to its average volume of 11,878. The business has a 50 day simple moving average of $161.94 and a two-hundred day simple moving average of $171.01. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64.

VanEck Biotech ETF Dividend Announcement

The company also recently declared a dividend, which was paid on Tuesday, December 24th. Investors of record on Monday, December 23rd were given a dividend of $1.2517 per share. The ex-dividend date was Monday, December 23rd.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of VanEck Biotech ETF by 5.8% during the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 24,324 shares of the company’s stock worth $4,096,000 after purchasing an additional 1,334 shares during the last quarter. Truist Financial Corp lifted its position in VanEck Biotech ETF by 3.8% during the second quarter. Truist Financial Corp now owns 2,703 shares of the company’s stock worth $455,000 after buying an additional 100 shares in the last quarter. International Assets Investment Management LLC boosted its stake in VanEck Biotech ETF by 10,376,390.9% during the third quarter. International Assets Investment Management LLC now owns 1,141,414 shares of the company’s stock worth $202,475,000 after buying an additional 1,141,403 shares during the last quarter. Tyler Stone Wealth Management grew its holdings in VanEck Biotech ETF by 79.5% in the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after buying an additional 652 shares in the last quarter. Finally, Coastline Trust Co acquired a new stake in shares of VanEck Biotech ETF in the 3rd quarter worth $59,000. Hedge funds and other institutional investors own 32.05% of the company’s stock.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.